Evan David Seigerman, BMO managing director, joins ‘Fast Money’ to discuss Novo sinking on its obesity drug data.
Source link
Trending
- Bank of America names Nvidia and these chip stocks as top 2025 picks
- What a 105-year-old told me about middle age before I turned 40
- Matt Gaetz sex, drug report released by House Ethics Committee
- Max Purcell admits doping violation: U.S. Open doubles champion enters provisional suspension
- Suspect in UnitedHealth executive’s killing pleads not guilty to murder, terrorism charges
- Here are our top 10 things to watch in the stock market Monday
- Biden commutes dozens of death row sentences to life without parole
- Wall Street’s unwanted S&P 500 stocks for 2025 may face declines
BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints
